person · Reporting owner

Schall Thomas J.

Disclosed activity across 2 companies

Tapewire entity: 39220
SEC CIK: 0001423084

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Immuneering CorpIMRX · Entity 5884	Director	June 11, 2026	June 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immuneering Corp

Report date June 11, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11	Direct	33,350	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ChemoCentryx, Inc.

Report date October 20, 2022 · Filed October 24, 2022

Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-20 transaction · row 1 1 source row Row 1 · 2022-10-20 · Disposition to issuer · Disposed 2,393,352 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83	Direct	Reported balance After 2022-10-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-20 · Disposition to issuer · Disposed 4,192 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83	Direct	Reported balance After 2022-10-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-20 · Disposition to issuer · Disposed 188,408 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $46.59	Direct	Reported balance After 2022-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-20 · Disposition to issuer · Disposed 2,502 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $46.59	Direct	Reported balance After 2022-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-20 · Disposition to issuer · Disposed 68,998 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.02	Direct	Reported balance After 2022-10-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-20 · Disposition to issuer · Disposed 7,912 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.02	Direct	Reported balance After 2022-10-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-20 · Disposition to issuer · Disposed 222,088 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.86	Direct	Reported balance After 2022-10-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-20 · Disposition to issuer · Disposed 11,693 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.86	Direct	Reported balance After 2022-10-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-20 · Disposition to issuer · Disposed 278,307 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.62	Direct	Reported balance After 2022-10-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-20 · Disposition to issuer · Disposed 262,431 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.62	Direct	Reported balance After 2022-10-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-20 · Disposition to issuer · Disposed 17,569 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.57	Direct	Reported balance After 2022-10-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-20 · Disposition to issuer · Disposed 285,812 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.57	Direct	Reported balance After 2022-10-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-20 · Disposition to issuer · Disposed 14,188 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19	Direct	Reported balance After 2022-10-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-10-20 · Disposition to issuer · Disposed 406,175 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19	Direct	Reported balance After 2022-10-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-10-20 · Disposition to issuer · Disposed 13,825 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.10	Direct	Reported balance After 2022-10-20 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-10-20 · Disposition to issuer · Disposed 8,231 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.10	Direct	Reported balance After 2022-10-20 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-10-20 · Disposition to issuer · Disposed 386,769 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.28	Direct	Reported balance After 2022-10-20 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-10-20 · Disposition to issuer · Disposed 7,002 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.28	Direct	Reported balance After 2022-10-20 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2022-10-20 · Disposition to issuer · Disposed 27,998 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-20 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2022-10-20 · Disposition to issuer · Disposed 239,934 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,

F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.

F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2026 Filed Jun 11, 2026 21:37 UTC	Immuneering Corp IMRX · Entity 5884	GrantStock Option · Derivative	33,350	$0.00 Strike: $4.12	$0.00	Disclosure SEC source: 0001790340-26-000072 · wk-form4_1781213861.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. Read SEC document
January 15, 2026 Filed Jan 20, 2026 14:17 UTC	Immuneering Corp IMRX · Entity 5884	PurchaseClass A Common Stock	21,645	$4.67	$101,041.02	Disclosure SEC source: 0001790340-26-000014 · wk-form4_1768918646.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,530 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.61 to $4.69. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document
June 27, 2025 Filed Jun 30, 2025 13:09 UTC	Immuneering Corp IMRX · Entity 5884	PurchaseClass A Common Stock	9,500	$3.66	$34,788.05	Disclosure SEC source: 0001790340-25-000089 · wk-form4_1751288953.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,885 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.6 to $3.73. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document
June 17, 2025 Filed Jun 18, 2025 13:11 UTC	Immuneering Corp IMRX · Entity 5884	PurchaseClass A Common Stock	40,485	$2.21	$89,277.52	Disclosure SEC source: 0001790340-25-000079 · wk-form4_1750252275.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,385 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.16 to $2.24. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document
June 13, 2025 Filed Jun 16, 2025 13:15 UTC	Immuneering Corp IMRX · Entity 5884	GrantStock Option · Derivative	33,350	$0.00 Strike: $1.90	$0.00	Disclosure SEC source: 0001790340-25-000073 · wk-form4_1750079729.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2035-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. Read SEC document
June 12, 2024 Filed Jun 13, 2024 20:26 UTC	Immuneering Corp IMRX · Entity 5884	GrantStock Option · Derivative	8,588	$0.00 Strike: $1.54	$0.00	Disclosure SEC source: 0001628280-24-028072 · wk-form4_1718310353.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,588 Underlying: Class A Common Stock · 8,588 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first. Read SEC document
March 22, 2024 Filed Mar 25, 2024 20:03 UTC	Immuneering Corp IMRX · Entity 5884	PurchaseClass A Common Stock	2,900	$2.55	$7,384.85	Disclosure SEC source: 0001415889-24-009028 · form4-03252024_080319.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,900 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.53 to $2.55. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document
March 11, 2024 Filed Mar 12, 2024 21:02 UTC	Immuneering Corp IMRX · Entity 5884	GrantStock Option · Derivative	35,000	$0.00 Strike: $5.93	$0.00	Disclosure SEC source: 0001415889-24-007651 · form4-03122024_090310.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Class A Common Stock · 35,000 shares Expires 2034-03-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on April 11, 2024, and will be fully vested and exercisable on March 11, 2027. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerRestricted Stock Unit · Derivative	239,934	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 20 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 239,934 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.exercise_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.expiration_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	27,998	Not disclosed Strike: $14.28	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 19 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,998 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	7,002	Not disclosed Strike: $14.28	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 18 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,002 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	386,769	Not disclosed Strike: $7.10	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 17 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 386,769 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	8,231	Not disclosed Strike: $7.10	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 16 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,231 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	13,825	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 15 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,825 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	406,175	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 14 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 406,175 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	14,188	Not disclosed Strike: $3.57	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 13 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,188 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	285,812	Not disclosed Strike: $3.57	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 12 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,812 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	17,569	Not disclosed Strike: $6.62	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 11 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,569 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	262,431	Not disclosed Strike: $6.62	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 10 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262,431 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	278,307	Not disclosed Strike: $10.86	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 9 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278,307 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	11,693	Not disclosed Strike: $10.86	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 8 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,693 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	222,088	Not disclosed Strike: $11.02	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 222,088 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	7,912	Not disclosed Strike: $11.02	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,912 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	68,998	Not disclosed Strike: $46.59	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,998 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	2,502	Not disclosed Strike: $46.59	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,502 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	188,408	Not disclosed Strike: $29.83	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188,408 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerStock Option · Derivative	4,192	Not disclosed Strike: $29.83	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · derivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,192 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document
October 20, 2022 Filed Oct 24, 2022 23:01 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Disposition to issuerCommon Stock	2,393,352	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-034075 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2 · price: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. Read SEC document
August 04, 2022 Filed Aug 8, 2022 23:41 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionStock Option (right to buy) · Derivative	130,000	Not disclosed Strike: $14.28	Not disclosed	Disclosure SEC source: 0001209191-22-044896 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 130,000 shares Expires 2023-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: As of August 4, 2022, and prior to this transaction, the exercised options were fully vested. Read SEC document
August 04, 2022 Filed Aug 8, 2022 23:41 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	SaleCommon Stock	130,000	$50.24	$6,531,733.00	Disclosure SEC source: 0001209191-22-044896 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,393,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $50.05 to $50.59 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
August 04, 2022 Filed Aug 8, 2022 23:41 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	130,000	$14.28	$1,856,400.00	Disclosure SEC source: 0001209191-22-044896 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,523,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 22, 2022 Filed Feb 26, 2022 01:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantStock Option (right to buy) · Derivative	192,600	Not disclosed Strike: $29.83	Not disclosed	Disclosure SEC source: 0001209191-22-013403 · doc4.xml · derivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,600 Underlying: Common Stock · 192,600 shares Expires 2032-02-22 F4 · price: Not applicable. F3 · derivative.exercise_date: The option was granted on February 22, 2022, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document
February 22, 2022 Filed Feb 26, 2022 01:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantRestricted Stock Units · Derivative	152,700	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-013403 · doc4.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,700 Underlying: Common Stock · 152,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on February 22, 2022, vests in four equal installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F2 · derivative.expiration_date: The restricted stock units awarded on February 22, 2022, vests in four equal installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	26,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · derivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,667 Underlying: Common Stock · 26,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F8 · derivative.exercise_date: The restricted stock units awarded on February 25, 2021, vests in three equal installments on January 1, 2022, January 1, 2023, and January 1, 2024, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F8 · derivative.expiration_date: The restricted stock units awarded on February 25, 2021, vests in three equal installments on January 1, 2022, January 1, 2023, and January 1, 2024, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	34,567	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,567 Underlying: Common Stock · 34,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F7 · derivative.exercise_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F7 · derivative.expiration_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	23,334	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F6 · derivative.exercise_date: The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F6 · derivative.expiration_date: The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Tax withholdingCommon Stock	45,698	$36.41	$1,663,864.18	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,393,352 F4 · shares: Represents shares withheld upon vesting of restricted stock units to satisfy tax withholding obligation. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	26,333	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · nonDerivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,439,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Shares were acquired upon vesting of restricted stock units awarded on February 25, 2021. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	34,567	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 3, 2020. Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:42 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	23,334	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001341 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,378,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 4, 2019. Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionStock Option (right to buy) · Derivative	6,988	Not disclosed Strike: $14.31	Not disclosed	Disclosure SEC source: 0001209191-21-068010 · doc4.xml · derivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,988 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: As of December 1, 2021, and prior to this transaction, the exercised options were fully vested. Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionStock Option (right to buy) · Derivative	38,948	Not disclosed Strike: $10.27	Not disclosed	Disclosure SEC source: 0001209191-21-068010 · doc4.xml · derivative · entry 3 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,948 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: As of December 1, 2021, and prior to this transaction, the exercised options were fully vested. Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	6,988	$14.31	$99,998.28	Disclosure SEC source: 0001209191-21-068010 · doc4.xml · nonDerivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:39 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionCommon Stock	38,948	$10.27	$399,995.96	Disclosure SEC source: 0001209191-21-068010 · doc4.xml · nonDerivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,347,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:17 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantStock Option (right to buy) · Derivative	54,600	Not disclosed Strike: $65.87	Not disclosed	Disclosure SEC source: 0001209191-21-015531 · doc4.xml · derivative · entry 2 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,600 Underlying: Common Stock · 54,600 shares Expires 2031-02-25 F4 · price: Not applicable. F3 · derivative.exercise_date: The option was granted on February 25, 2021, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:17 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	GrantRestricted Stock Units · Derivative	79,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-015531 · doc4.xml · derivative · entry 1 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on February 25, 2021, vests in three equal installments on January 1, 2022, January 1, 2023, and January 1, 2024, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F2 · derivative.expiration_date: The restricted stock units awarded on February 25, 2021, vests in three equal installments on January 1, 2022, January 1, 2023, and January 1, 2024, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2021 Filed Jan 8, 2021 01:40 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	34,566	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002636 · doc4.xml · derivative · entry 7 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,134 Underlying: Common Stock · 34,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F8 · derivative.exercise_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F8 · derivative.expiration_date: The restricted stock units awarded on March 3, 2020, vest in three equal installments on January 1, 2021, January 1, 2022, and January 1, 2023, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2021 Filed Jan 8, 2021 01:40 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	23,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002636 · doc4.xml · derivative · entry 6 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,334 Underlying: Common Stock · 23,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F7 · derivative.exercise_date: The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F7 · derivative.expiration_date: The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2021 Filed Jan 8, 2021 01:40 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Exercise / conversionRestricted Stock Units · Derivative	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002636 · doc4.xml · derivative · entry 5 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F5 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F6 · derivative.exercise_date: The restricted stock units awarded on March 5, 2018, vest in three equal installments on January 1, 2019, January 1, 2020, and January 1, 2021, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F6 · derivative.expiration_date: The restricted stock units awarded on March 5, 2018, vest in three equal installments on January 1, 2019, January 1, 2020, and January 1, 2021, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document
January 01, 2021 Filed Jan 8, 2021 01:40 UTC	ChemoCentryx, Inc. CCXI · Entity 122928	Tax withholdingCommon Stock	47,576	$61.92	$2,945,905.92	Disclosure SEC source: 0001209191-21-002636 · doc4.xml · nonDerivative · entry 4 Schall Thomas J. · CIK 0001423084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,308,880 F4 · shares: Represents shares withheld upon vesting of restricted stock units to satisfy tax withholding obligation. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.